Biomarin's Deal Sparks 17% Jump

27 days ago

"Finally, a Biomarin company, Biomarin, ticker BMRN. It's up 17% - the biggest jump since November 2016 on deal news. They agreed to buy Amicus Therapeutics for about $4.8 billion. And this is a company that has treatments for rare diseases, so investors are taking this as now Biomarin is going to be able to expand its portfolio of treatments. It has pricing power for these rare diseases."

Biomarin shares surged 17% following the announcement of its $4.8 billion acquisition of Amicus Therapeutics, with investors expecting expanded treatment portfolios and strengthened pricing power in the rare disease market.

Related Stocks